Grifols (GIFLF) EPS (Weighted Average and Diluted) (2010 - 2020)
Grifols (GIFLF) reported EPS (Weighted Average and Diluted) of -$74918.8 for Q1 2020, down 5.28% on a YoY basis from -$79091.5 in Q2 2019, and up 66.32% quarter-over-quarter from -$222472.2 in Q4 2019.
Grifols (GIFLF) EPS (Weighted Average and Diluted) (2010 - 2020) Analysis & Trends
Grifols has reported EPS (Weighted Average and Diluted) for 10 years, with the latest figure at -$74918.8 in Q1 2020.
- For the quarter ending Q1 2020, EPS (Weighted Average and Diluted) fell 5.28% year-over-year to -$74918.8; the trailing twelve-month figure through Dec 2021 stood at $1.1 million (up 7.05% YoY), and the FY2025 full-year result was $0.69, up 179.43% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2020 stood at -$74918.8, up from -$222472.2 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $688298.3 in Q3 2016, with the low at -$222472.2 in Q4 2019.
- Historically, EPS (Weighted Average and Diluted) has averaged $98450.3 across 5 years, with a median of -$64670.1 in 2018.
- Annual changes were most pronounced in 2016 — EPS (Weighted Average and Diluted) soared 13149259.48% — and 2017, when it plunged 119919.01%.
- Grifols' EPS (Weighted Average and Diluted) stood at $688298.3 in 2016, then sank by 131.11% to -$214156.1 in 2017, then increased by 9.14% to -$194586.4 in 2018, then dropped by 14.33% to -$222472.2 in 2019, then surged by 66.32% to -$74918.8 in 2020.
- The last three EPS (Weighted Average and Diluted) figures came in at -$74918.8 (Q1 2020), -$222472.2 (Q4 2019), and -$71164.3 (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | 8.26 |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 2.14 |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 0.39 |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | -1.72 |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | 3.34 |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 1.61 |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | 0.47 |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | 1.31 |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -74,918.82 |
| Dec 31, 2019 | -222,472.25 |
| Mar 31, 2019 | -71,164.33 |
| Dec 31, 2018 | -194,586.40 |
| Jun 30, 2018 | 373,557.45 |
| Mar 31, 2018 | -66,299.00 |
| Dec 31, 2017 | -214,156.14 |
| Jun 30, 2017 | 565,853.66 |
| Mar 31, 2017 | -63,041.19 |
| Sep 30, 2016 | 688,298.31 |
| Jun 30, 2016 | 460,279.49 |
| Mar 31, 2016 | 52.61 |
| Dec 31, 2015 | 173.30 |
| Sep 30, 2015 | 237,464.41 |
| Jun 30, 2015 | 3.50 |
| Mar 31, 2015 | 57.51 |
| Sep 30, 2013 | 106,629.11 |
| Jun 30, 2013 | 169,996.30 |
| Mar 31, 2013 | 337,044.44 |
| Dec 31, 2012 | 152,374.67 |